{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:33:46Z","timestamp":1772487226033,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jprasurg.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bjps.2024.09.012","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T08:38:02Z","timestamp":1725698282000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["DaxibotulinumtoxinA for injection to treat moderate or severe glabellar lines: A randomized, multicenter, Phase III, double-blind, placebo-controlled trial in China"],"prefix":"10.1016","volume":"99","author":[{"given":"Yun","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjps.2024.09.012_bib1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A Multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2024.09.012_bib2","first-page":"776","article-title":"Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials","volume":"40","author":"Jones","year":"2014","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib3","unstructured":"Ipsen. Dysport prescribing information; 2020: 2022. https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/2020\/07\/10002305\/DYS-US-004998_Dysport-PI-July-2020.pdf. Accessed July, 2024."},{"key":"10.1016\/j.bjps.2024.09.012_bib4","unstructured":"Allergan I. BOTOX Cosmetic prescribing information; 2019: 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103000s5306lbl.pdf. Accessed July, 2024."},{"key":"10.1016\/j.bjps.2024.09.012_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00266-022-03164-3","article-title":"Efficacy and safety of abobotulinumtoxinA for the treatment of glabellar lines in Chinese patients: a pivotal, phase 3, randomized, double-blind and open-label phase study","volume":"47","author":"Wu","year":"2023","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1524-4725.2009.01390.x","article-title":"Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study","volume":"36","author":"Wu","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13060370","article-title":"Lantox\u2014the Chinese botulinum toxin drug\u2014complete english bibliography and comprehensive formalised literature review","volume":"13","author":"Dressler","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.bjps.2024.09.012_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/asj\/sjac019","article-title":"Efficacy and safety of letibotulinumtoxin A in the treatment of glabellar lines: a randomized, double-blind, multicenter, placebo-controlled phase 3 study","volume":"42","author":"Mueller","year":"2022","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.bjps.2024.09.012_bib9","unstructured":"UK CP. Summary of Product Characteristics: Letybo; 2022: 2022. https:\/\/www.medicines.org.uk\/emc\/product\/13707\/smpc#gref. Accessed June, 2024."},{"key":"10.1016\/j.bjps.2024.09.012_bib10","first-page":"28","article-title":"A phase III study of incobotulinumtoxinA in the treatment of glabellar frown lines","volume":"4","author":"Imhof","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.bjps.2024.09.012_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport((R))), onabotulinumtoxinA (Botox((R))), and incobotulinumtoxinA (Xeomin((R))) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.bjps.2024.09.012_bib12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2024.09.012_bib15","unstructured":"U.S. Food and Drug Administration. Guidance for Industry Upper Facial Lines: Developing Botulinum Toxin Drug Products; 2014: 2022. https:\/\/www.fda.gov\/files\/drugs\/published\/Upper-Facial-Lines---Developing-Botulinum-Toxin-Drug-Products.pdf. Accessed June, 2024."},{"key":"10.1016\/j.bjps.2024.09.012_bib16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of daxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bjps.2024.09.012_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/DSS.0000000000002463","article-title":"A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.36849\/JDD.6130","article-title":"AbobotulinumtoxinA treatment of glabellar lines using a new reconstitution and injection volume: randomized, placebo-controlled data","volume":"20","author":"Schlessinger","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.bjps.2024.09.012_bib19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00266-016-0682-1","article-title":"Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis","volume":"40","author":"Jia","year":"2016","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00266-008-9197-8","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects","volume":"32","author":"Kane","year":"2008","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00266-008-9199-6","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects","volume":"32","author":"Harii","year":"2008","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/asj\/sjac246","article-title":"Efficacy and safety of daxibotulinumtoxinA for injection in the treatment of glabellar lines by age and race: subgroup analysis of the SAKURA Clinical Trials","volume":"43","author":"Solish","year":"2023","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.bjps.2024.09.012_bib23","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/DSS.0000000000003211","article-title":"Progressive improvement in static glabellar lines after repeated treatment with daxibotulinumtoxinA for injection","volume":"47","author":"Glogau","year":"2021","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.bjps.2024.09.012_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated onabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"}],"container-title":["Journal of Plastic, Reconstructive & Aesthetic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174868152400559X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174868152400559X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:05:43Z","timestamp":1737637543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174868152400559X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S174868152400559X"],"URL":"https:\/\/doi.org\/10.1016\/j.bjps.2024.09.012","relation":{},"ISSN":["1748-6815"],"issn-type":[{"value":"1748-6815","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DaxibotulinumtoxinA for injection to treat moderate or severe glabellar lines: A randomized, multicenter, Phase III, double-blind, placebo-controlled trial in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Plastic, Reconstructive & Aesthetic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjps.2024.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.","name":"copyright","label":"Copyright"}]}}